Initially described by Adolfo Lutz in 1908, paracoccidiodomycosis (PCM) is considered to be the most prevalent endemic systemic mycosis in Brazil and other Latin American countries. Based on data generated by epidemiological surveys employing intradermal tests for paracoccidioidin, the prevalence of *Paracoccidioides brasiliensis* infection in these endemic areas may be as high as 50% to 75% among the adult population, and almost 10 million people may have been infected by this pathogen (1, 21).

One hundred years after the original description of PCM, we may celebrate several instances of substantial progress in characterizing *P. brasiliensis*. These advances include the complete sequencing of its genome, the evaluation of molecular factors that trigger the transition from hyphal to yeast form, the determination of the most relevant virulence factors as well as the importance of the glycoprotein gp43 in terms of fungal pathogenesis and mediating host-immune response. In addition, several well-conducted studies have consistently characterized the cell-mediated immune mechanisms needed to contain *P. brasiliensis* infection. In this regard, Type 1 (Th1) response, with high levels of IFN-γ and IL-2, has been related to immunity in animal and human models of the disease. On the other hand, susceptibility is linked to Type 2 (Th2) response, and production of IL-4, IL-5, IL-10 and TGF-β (2, 4, 8, 11, 13, 14, 17, 19).

In terms of diagnosis, the advances are also remarkable since today we have available both several sensitive and specific methods for detecting anti-*P. brasiliensis* antibodies and ELISA assays for detecting specific antigens of the fungus in different biological fluids. Different polymerase chain reaction-based methods exist not only for identifying PCM, but also for genotyping *P. brasiliensis* isolates (4, 7, 9, 12, 16, 21).

Antifungal treatment of patients with paracoccidioidomycosis is still controversial. The few studies available on antifungal treatment of PCM enrolled a limited number of patients, and were neither randomized nor statistically robust (18, 21). Thus, they did
not permit consistent conclusions about comparative efficacy analysis. Considering
the limited data generated by well-conducted clinical trials in PCM, most guidelines
for treating patients with this fungal infection are strongly based on expert opinions
(18).
Long-term therapy consisting mostly of itraconazole or the combination of
trimethoprim and sulfamethoxazole is usually required to achieve good clinical
response and avoid relapses that are clearly correlated with drug toxicity, high costs
and abandonment of treatment by patients (1, 18, 21). Recently, Queiroz-Telles et al.
(15) demonstrated that although voriconazole is a safe alternative therapy for
patients with PCM, it still requires long periods of treatment.
Besides the long periods of antifungal therapy required by these patients, relapses
remain a significant problem in clinics. The non-responsive severely ill patients
represent an unsolved problem for the conventional therapeutic approach. Patients
who receive antifungal therapy but do not develop a stable Th1 response against the
fungal pathogen are more prone to relapse (1, 18, 21).
Despite all scientific progress towards the characterization of \textit{P. brasiliensis} and its
pathogenesis in animal and human models, as well as the standardization of
sensitive laboratory tests to diagnose PCM, this endemic mycosis remains a major
cause of disability and death among rural young adult workers during their most
productive years of life. This phenomenon is partially related to the social and
economic status of the target population for this disease, mostly represented by rural
workers with low incomes and limited access to a public or private health system. It is
important to mention that limited economic resources may impair the host response
to fungal infection and hinder the early detection of infected patients by the health
care system. Consequently, at the time most patients are diagnosed with fungal
infection, they are already severely ill with multiple organs compromised by the
disease (21).
There is a consensus that respiratory failure and adrenal insufficiency are two of the
most commonly reported sequelae among adult patients who develop PCM. A study
carried out by Tobón \textit{et al.} (20) documented lung sequelae among 47 adult patients
with PCM treated with itraconazole. Fibrosis was observed in 31.8\% of the patients at
diagnosis and had not cleared at the end of the observation period in any of these
patients. After starting treatment, some of the others patients also developed fibrosis
and by the end of the follow-up period the disease was detected in 53.2\% of patients
overall. Adrenal dysfunction secondary to PCM may be detected in 10% to 44% of patients evaluated by different functional tests, including evaluation of cortisol synthesis by infusion of Cortrosyn® (exogenous adrenocorticotropic hormone). Symptomatic adrenal dysfunction has been reported in 3% to 6% of patients (5).

Based on data obtained from the Brazilian Health Ministry’s Mortality Information System, a total of 3,181 PCM deaths were reported in Brazil between 1980 and 1995, corresponding to a mortality rate of 1.45 deaths per million inhabitants (6). A recent publication using the same mentioned death registry data attempted to exclusively evaluate the mortality rate of PCM reported in the state of Parana, an area highly endemic for this fungal infection, in which the average PCM mortality rate was 3.48 per million inhabitants, ranking this fungal infection as the fifth most common cause of death among all chronic infections with high prevalence in that particular region (3).

In conclusion, it is possible to suggest that the scientific community may celebrate several relevant contributions obtained in the study of this pathogen’s biology, mechanisms of infection and host-response. New sensitive and specific diagnostic tools were developed but, unfortunately, they were not incorporated into the routine of most public medical centers due to cost issues and lack of human resources trained in medical mycology. New efforts are necessary to enable early diagnosis of paracoccidioidomycosis and to develop alternative therapeutic strategies against the fungus to improve patient compliance and final efficiency of the regimens (21). Recently, Travassos and colleagues (21) have demonstrated that a peptide-based vaccine may induce a Th1 response in Balb/c mice infected by *P. brasiliensis*, resulting in a significant reduction in the fungal load. This finding suggests that in the future we may have patients treated by immune stimulation with peptide vaccine as an adjuvant to antifungal drugs in order to shorten the treatment period of and decrease the number of relapses and sequels (10, 21).
REFERENCES


**CORRESPONDENCE TO:**
ARNALDO LOPES COLOMBO, Disciplina de Infectologia, Departamento de Medicina da Universidade Federal de São Paulo, Rua Botucatu, 740, Vila Clementino, 04023-062, São Paulo, SP, Brasil. Phone: +55 11 5082 4100. Email: colomboal@terra.com.br.